Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 14, 2014 - Issue 3
Submit an article Journal homepage
281
Views
12
CrossRef citations to date
0
Altmetric
Reviews

Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature

Ramón San MiguelDepartment of Pharmacy, Complejo Hospitalario de Navarra, Pamplona, SpainCorrespondence[email protected]
,
Vicente Gimeno-BallesterDepartment of Pharmacy, Hospital Universitario Miguel Servet, Zaragoza, Spain
&
Javier MarClinical Management Unit, Hospital ‘Alto Deba’, Mondragon, Spain
Pages 387-402 | Published online: 23 Apr 2014

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Vicente Gimeno-Ballester, Miguel Ángel Simón, Cristina Trigo, Javier Mar & Ramón San Miguel. (2016) Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence. Expert Review of Gastroenterology & Hepatology 10:11, pages 1289-1303.
Read now
Scott J. Johnson, Hélène Parisé, Suchin Virabhak, Ivana Filipovic, Jennifer C. Samp & Derek Misurski. (2016) Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. Journal of Medical Economics 19:10, pages 983-994.
Read now
Kirsten Westerhout, Maarten Treur, Angelika Mehnert, Katie Pascoe, Imran Ladha & Jonathan Belsey. (2015) A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service. Journal of Medical Economics 18:10, pages 838-849.
Read now

Articles from other publishers (9)

László Szilberhorn, Zoltán Kaló & Tamás Ágh. (2018) Cost-Effectiveness of Second-generation Direct-acting Antiviral Agents in Chronic HCV Infection: A Systematic Literature Review. Antiviral Therapy 24:4, pages 247-259.
Crossref
Maria Stepanova & Zobair M. Younossi. (2017) Economic Burden of Hepatitis C Infection. Clinics in Liver Disease 21:3, pages 579-594.
Crossref
Lorenzo Giovanni Mantovani, Paolo Angelo Cortesi & Mario Strazzabosco. (2016) Effective but costly: How to tackle difficult trade‐offs in evaluating health improving technologies in liver diseases. Hepatology 64:4, pages 1331-1342.
Crossref
Javier Mar, Lorea Mar-Barrutia, Vicente Gimeno-Ballester & Ramón San Miguel. (2016) Análisis coste-efectividad del tratamiento de la hepatitis C crónica con sofosbuvir-simeprevir en pacientes con genotipo 1 y fibrosis avanzada. Medicina Clínica 146:2, pages 61-64.
Crossref
Javier Mar, Lorea Mar-Barrutia, Vicente Gimeno-Ballester & Ramón San Miguel. (2016) Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis. Medicina Clínica (English Edition) 146:2, pages 61-64.
Crossref
Ramón San Miguel, Vicente Gimeno-Ballester, Antonio Blázquez & Javier Mar. (2015) Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut 64:8, pages 1277-1288.
Crossref
Jona T Stahmeyer, Siegbert Rossol & Christian Krauth. (2015) Outcomes, costs and cost–effectiveness of treating hepatitis C with direct acting antivirals. Journal of Comparative Effectiveness Research 4:3, pages 267-277.
Crossref
Vasilios Fragoulakis, Christina Mitropoulou, Marc S. Williams & George P. Patrinos. 2015. Economic Evaluation in Genomic Medicine. Economic Evaluation in Genomic Medicine 97 113 .
Susan R. Snyder, Christina Mitropoulou, George P. Patrinos & Marc S. Williams. (2014) Economic Evaluation of Pharmacogenomics: A Value-Based Approach to Pragmatic Decision Making in the Face of Complexity. Public Health Genomics 17:5-6, pages 256-264.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.